Estrella Immunopharma
ESLA
19 hedge funds and large institutions have $32.4M invested in Estrella Immunopharma in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
19% more funds holding
Funds holding: 16 → 19 (+3)
13% more capital invested
Capital invested by funds: $28.7M → $32.4M (+$3.65M)
7.72% more ownership
Funds ownership: 61.23% → 68.95% (+7.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HHGC
Hunting Hill Global Capital
New York
|
+$2.61M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$1.95M |
| 3 |
LA
Linden Advisors
New York
|
+$1.64M |
| 4 |
WA
Whitebox Advisors
Minneapolis,
Minnesota
|
+$901K |
| 5 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$870K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$2.85M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.95M |
| 3 |
MSU
Mizuho Securities USA
New York
|
-$866K |
ESLA Hedge Fund Activity: Q4 2021 in Review
19 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q4 2021, worth a combined $32.4M — up 13% from $28.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ESLA positions and 3 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Hunting Hill Global Capital, adding an estimated $2.61M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $2.85M sold.
- 19 institutional investors held Estrella Immunopharma (ESLA) as of Q4 2021, up from 16 in Q3 2021.
- Funds reported $32.4M of Estrella Immunopharma stock for Q4 2021, up 13% quarter-over-quarter.
- 6 funds opened new Estrella Immunopharma positions in Q4 2021 and 3 closed out, a net change of +3 holders.
- The largest Estrella Immunopharma buyer in Q4 2021 was Hunting Hill Global Capital, an estimated $2.61M added.
- The largest Estrella Immunopharma seller in Q4 2021 was K2 Principal Fund, an estimated $2.85M sold.
Based on aggregated 13F filings for Q4 2021.